Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

The risks and benefits of structured treatment interruption (STI) in HIV-1-infected subjects are not fully understood. A pilot study was performed to compare STI with continuous highly active antiretroviral therapy (HAART) in chronic HIV-1-infected subjects with HIV-1 plasma RNA levels (VL) <400 copies per ml and CD4+ T cells >400 per μl. CD4+ T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-γ-producing HIV-1-specific CD8+ and CD4+ T cells were measured in all subjects. STIs of 1-month duration separated by 1 month of HAART, before a final 3-month STI, resulted in augmented CD8+ T cell responses in all eight STI subjects (P = 0.003), maintained while on HAART up to 22 weeks after STI, and augmented neutralization titers to autologous HIV-1 isolate in one of eight subjects. However, significant decline of CD4+ T cell count from pre-STI level, and VL rebound to pre-HAART baseline, occurred during STI (P = 0.001 and 0.34, respectively). CD4+ T cell counts were regained on return to HAART. Control subjects (n = 4) maintained VL <400 copies per ml and stable CD4+ T cell counts, and showed no enhancement of antiviral CD8+ T cell responses. Despite increases in antiviral immunity, no control of VL was observed. Future studies of STI should proceed with caution.

[1]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[2]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[3]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[4]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[5]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[6]  D. Montefiori,et al.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. , 1996, The Journal of infectious diseases.

[7]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[8]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[9]  D. Montefiori,et al.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells , 1997, Journal of virology.

[10]  C. Rouzioux,et al.  High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. , 1998, AIDS.

[11]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[12]  C. Sabin,et al.  Rebound of HIV-1 viral load after suppression to very low levels. , 1998, AIDS.

[13]  V. Calvez,et al.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.

[14]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[15]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[16]  P. Reiss,et al.  Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.

[17]  B. Walker,et al.  Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy , 1999, Journal of Virology.

[18]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Nixon,et al.  Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. , 1999, The Journal of infectious diseases.

[20]  A. Trkola,et al.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.

[21]  M. Nowak,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.

[22]  J. Lisziewicz,et al.  Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.

[23]  E. Rosenberg,et al.  Association between Virus-Specific Cytotoxic T-Lymphocyte and Helper Responses in Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[24]  R. Paredes,et al.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.

[25]  D. Nixon,et al.  Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.

[26]  M. Saag,et al.  Recurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report , 2000, Annals of Internal Medicine.

[27]  G. M. Ortiz,et al.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.

[28]  V. Calvez,et al.  Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 , 2000, The Journal of Immunology.

[29]  S. Rowland-Jones,et al.  Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection , 2000, AIDS.

[30]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[31]  J. Margolick,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeficiency , 2000, Journal of Virology.

[32]  C. Yoder,et al.  Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy , 2000, AIDS.

[33]  D. Nixon,et al.  Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. , 2000, AIDS.

[34]  C. Yoder,et al.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression , 2000, AIDS.

[35]  R. Koup,et al.  Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Histocompatibility Complex Class I Haplotype , 2000, Journal of Virology.

[36]  M. Schambelan,et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .

[37]  W. Miller,et al.  Sex differences in nevirapine rash. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  V. Calvez,et al.  Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection , 2001, Journal of Virology.

[39]  J. Kahn,et al.  Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.